Syrna Therapeutics, the first structure-guided drug discovery company focusing on mRNA, is advancing small-molecule translation inhibitors that modify mRNA of disease-causing proteins to prevent expression. Our 3D structure-informed integrated discovery platform identifies and validates novel small-molecule drug target sites that are unique to each individual mRNA. We make small-molecule covalent translation inhibitors that selectively modify mRNA at the target site and prevent protein from being made from the mRNA. This mechanism of action is universal because it does not depend on the native biological functions of the mRNA where the compound binds. Our inhibitors are highly selective because of the combined selectivity of non-covalent binding and covalent bond formation. Our structural biology capabilities allow us to achieve 3D structures of RNA with compound bound to guide medicinal chemistry.